Genexis, a cruelty-conscious protein biotechnology company based in Gujarat, with a mission to create ethical and sustainable animal-origin-free recombinant products ranging from cellular agriculture, pharmaceuticals, cosmetics, and biopharmaceutical research. In July 2025, Genexis raised ₹4 crore via a seed round from GVFL (Gujarat Venture Finance Limited), which invests in budding enterprises.
This investment comes at a time when India is growing as a biotech hub, as reported by the India Bioeconomy Report 2025, that India’s bioeconomy reached $165.7 billion in 2024, contributing 4.25% to its GDP and further projected to grow to $300 billion by 2030 and $1 trillion by 2047. This demanding sector requires more investment and exploring untapped solutions of biotech formulations.
Why does GVFL invest capital in Genexis?
GVFL has over 100 companies, with areas of investment including the Biotechnology Industry, Deep Tech, AI, as well as innovative and impact-driven startups. Mihir Joshi, Managing Director of GVFL, explained the rationale behind the investment. It’s not merely a capital investment, but rather an innovation investment.
Genexis is currently solving one of the trending problems in the Biotech industry, as said by Joshi, “Genexis is solving a critical gap in India’s biotech value chain by enabling high-quality, animal-origin-free protein production at scale.” This solution is a turning point for the bioinnovation space, represents a significant opportunity. He further lauded the company, “Its R&D strength, infrastructure, and early traction position it well to serve growing demand across biopharma, food-tech, and life sciences.”
How the GVFL investment contribute to Genexis’s expansion?
In the preceding years, Genexis built a class 10,000 cleanroom facility and aims to initiate a GMP (Good Manufacturing Practice) compliant unit. With the recent ₹4 crore investment, it will disburse the funds towards R&D and product development, scaling animal-origin-free protein development via precision fermentation, and for the distribution and commercialization of their products.
Genexis’s pivotal partnership and recognition
Genexis collaborates with the lead partner to expand its company and establish its footprint in the biotech industry. With its breakthrough innovation, Genexis is expanding its global contributions.
- Genexis signs MoU (Memorandum of Understanding) with the government of Gujarat for advancing sustainable biomanufacturing in India, 2023.
- Selected in Global Bio India, 2024, for Genexis for its innovative products recognized globally.
Genexis vision
“At Genexis Biotech, we are building India’s deeptech backbone for animal-origin-free protein production,” said Vipul Kumar, co-founder of Genexis. It also plans to collaborate shortly with
- Contract Development and Manufacturing Organisations (CDMOs) for marketing purposes and product advancement.
- Entering in the cosmetic industry for cutting-edge development in encapsulated growth formulations.
Through these partnerships, Genexis stimulates next-generation biotech solutions through its breakthrough innovation. It is also redefining India’s recombinant technology. With all the investments and partnerships, Genexis is positioned to build an eco-conscious biotech environment.
